Universal Beteiligungs und Servicegesellschaft mbH Raises Stock Holdings in Exelixis, Inc. $EXEL

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Exelixis by 6.7% in Q4 to 530,120 shares (about 0.20% of the company), valued at roughly $23.25 million.
• Exelixis beat Q4 EPS expectations with $0.94 vs. $0.74 estimated while revenue of $598.7M slightly missed estimates; the stock trades in the mid‑$40s, market cap ≈ $11.4B, and the consensus analyst rating is "Hold" with a $47 average price target.
• Significant insider selling occurred during the quarter—362,849 shares worth about $15.9 million were sold—while institutional investors own 85.27% of the stock and insiders retain 2.82%.

Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 6.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 530,120 shares of the biotechnology company's stock after buying an additional 33,329 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.20% of Exelixis worth $23,246,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Evergreen Capital Management LLC raised its holdings in shares of Exelixis by 44.2% in the fourth quarter. Evergreen Capital Management LLC now owns 7,858 shares of the biotechnology company's stock worth $344,000 after buying an additional 2,408 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Exelixis by 29.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 95,344 shares of the biotechnology company's stock worth $4,179,000 after buying an additional 21,688 shares during the period. Krilogy Financial LLC raised its holdings in shares of Exelixis by 50.3% in the fourth quarter. Krilogy Financial LLC now owns 30,902 shares of the biotechnology company's stock worth $1,348,000 after buying an additional 10,338 shares during the period. Earned Wealth Advisors LLC raised its holdings in shares of Exelixis by 33.4% in the fourth quarter. Earned Wealth Advisors LLC now owns 8,277 shares of the biotechnology company's stock worth $363,000 after buying an additional 2,072 shares during the period. Finally, Merit Financial Group LLC raised its holdings in shares of Exelixis by 25.4% in the fourth quarter. Merit Financial Group LLC now owns 86,956 shares of the biotechnology company's stock worth $3,811,000 after buying an additional 17,615 shares during the period. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Stock Down 2.4%

Shares of NASDAQ EXEL opened at $44.94 on Friday. The business has a fifty day simple moving average of $43.26 and a two-hundred day simple moving average of $42.61. The firm has a market cap of $11.42 billion, a PE ratio of 16.22, a price-to-earnings-growth ratio of 1.03 and a beta of 0.42. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.20. The business had revenue of $598.66 million during the quarter, compared to analyst estimates of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.Exelixis's revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.55 EPS. On average, research analysts expect that Exelixis, Inc. will post 3.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on EXEL. Royal Bank Of Canada reduced their price target on Exelixis from $46.00 to $43.00 and set a "sector perform" rating on the stock in a report on Monday, March 2nd. Zacks Research downgraded Exelixis from a "strong-buy" rating to a "hold" rating in a report on Thursday, March 5th. Wall Street Zen downgraded Exelixis from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 18th. Stifel Nicolaus increased their price target on Exelixis from $43.00 to $44.00 and gave the stock a "hold" rating in a report on Wednesday, February 11th. Finally, Weiss Ratings reiterated a "buy (b)" rating on shares of Exelixis in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Exelixis currently has an average rating of "Hold" and an average price target of $47.00.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director Jack L. Wyszomierski sold 99,574 shares of Exelixis stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total transaction of $4,382,251.74. Following the completion of the sale, the director directly owned 279,942 shares of the company's stock, valued at $12,320,247.42. The trade was a 26.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Brenda Hefti sold 18,669 shares of Exelixis stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $44.01, for a total value of $821,622.69. Following the sale, the senior vice president directly owned 96,512 shares of the company's stock, valued at approximately $4,247,493.12. This trade represents a 16.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 362,849 shares of company stock worth $15,917,463 over the last quarter. Insiders own 2.82% of the company's stock.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.